Scholarlink

<p>Mesenchymal stem cells (MSCs) effectively treat steroid-refractory acute graft-versus-host disease (aGVHD). However, their impact on patients with both steroid-refractory aGVHD (SR-aGVHD) and idiopathic pneumonia syndrome (IPS) is unclear. This retrospective study analyzed 24 patients who received MSCs as a secondary treatment for SR-aGVHD, including 6 who also had IPS. The 180-day overall survival rate was 52.0%, with a relapse rate of 13.3% and non-relapse mortality at 34.7%. The clinical course was compared between the six patients with concurrent IPS and SR-aGVHD who received MSCs and the 36 IPS patients who did not receive MSCs. The 6 MSC-treated patients had a higher 2-year overall survival rate than the control group, at 83.3% versus 61.1%, with all patients showing reduced oxygen requirements and improved imaging findings. Among the five patients who survived longer than 2&#xa0;months after MSC therapy, the median time to complete oxygen therapy was 28&#xa0;days, and steroid doses were reduced by 25% at the 2-month mark. Some patients showed improved pulmonary function after MSC therapy. These findings support MSCs as a promising treatment for SR-aGVHD and suggest potential benefits in IPS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic impact of mesenchymal stem cells on idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation

  • 期刊论文

  • 发表日期：

    2025年6月9日

查看全文
  • Chihiro Kamoi,
  • Toshiki Terao,
  • Yui Kambara,
  • Keisuke Seike,
  • Hideaki Fujiwara,
  • Noboru Asada,
  • Daisuke Ennishi,
  • Hisakazu Nishimori,
  • Keiko Fujii,
  • Nobuharu Fujii,
  • Yoshinobu Maeda,
  • Ken-ichi Matsuoka

摘要

Mesenchymal stem cells (MSCs) effectively treat steroid-refractory acute graft-versus-host disease (aGVHD). However, their impact on patients with both steroid-refractory aGVHD (SR-aGVHD) and idiopathic pneumonia syndrome (IPS) is unclear. This retrospective study analyzed 24 patients who received MSCs as a secondary treatment for SR-aGVHD, including 6 who also had IPS. The 180-day overall survival rate was 52.0%, with a relapse rate of 13.3% and non-relapse mortality at 34.7%. The clinical course was compared between the six patients with concurrent IPS and SR-aGVHD who received MSCs and the 36 IPS patients who did not receive MSCs. The 6 MSC-treated patients had a higher 2-year overall survival rate than the control group, at 83.3% versus 61.1%, with all patients showing reduced oxygen requirements and improved imaging findings. Among the five patients who survived longer than 2 months after MSC therapy, the median time to complete oxygen therapy was 28 days, and steroid doses were reduced by 25% at the 2-month mark. Some patients showed improved pulmonary function after MSC therapy. These findings support MSCs as a promising treatment for SR-aGVHD and suggest potential benefits in IPS.